Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunRISe-2: TAR-200 + cetrelimab vs chemoradiotherapy in muscle-invasive bladder cancer without cystectomy
jRCT2071200088Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised trial of gemcitabine-releasing intravesical system and cetrelimab in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Bladder-intact event-free survival (BI-EFS). Started May 2021; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on jRCT2071200088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200088.